Outcome of hepatitis C patients in a community with predominant genotype 3 with standard-of-care treatment before and after advent of direct-acting antivirals: A retrospective-cum-prospective study
CONCLUSIONS: (i) In retrospective group: The overall efficacy (sustained viral response at 24 weeks [SVR-24]) of pegylated interferon a2a and ribavirin regimen was 90.96%. (ii) In prospective group: The efficacy (SVR) of different regimens was found to be as: sofosbuvir + ribavirin + daclatasvir (SVR-24, 83.33%); sofosbuvir + ribavirin (SVR-12, 94.57%); and sofosbuvir + daclatasvir (SVR-12, 98.00%).
Source: Indian Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Showkat Ahmad Kadla Mohamad Amin Dar Nisar Ahmad Shah Bilal Ahmad Khan Asif Iqbal Shah Rupakshi Pathania Shagufta Parveen Source Type: research
More News: Cancer & Oncology | Carcinoma | Cirrhosis | Databases & Libraries | Drugs & Pharmacology | Gastroenterology | Hepatitis | Hepatitis C | Hepatocellular Carcinoma | India Health | Liver Cancer | Study